Webinar: July 22, 2025 | 11:00AM EST
In this webinar, you will learn:
- How to efficiently filter out non-specific binders early on to focus only on antibodies with true functional potential.
- Strategies to isolate highly specific anti-idiotype antibodies that avoid cross-reactivity with natural IgGs.
- The benefits of combining advanced enrichment techniques with proteomics to discover both blocking (type 1) and non-blocking (type 2) anti-idiotypes with improved affinity and specificity.
Anti-Idiotype Antibody Discovery
Not all binders are created equal, and sequencing them all is inefficient. A test-then-express approach eliminates non-specific binders early in the workflow, saving time and increasing the likelihood of identifying true functional hits.
In this webinar, we’ll explore how functional pre-selection strategies streamline anti-idiotype antibody discovery by enriching only the binders that matter.
The main challenge in anti-idiotypic antibody discovery is finding antibodies that are highly specific to the therapeutic antibody, without cross-reacting with naturally circulating IgGs. Our workflow leverages advanced protein enrichment and depletion strategies to isolate functionally relevant anti-idiotype subtypes before sequencing, significantly boosting discovery efficiency.
Using this targeted enrichment approach, we produced polyclonal antibodies with lower off-target binding to human IgG than commercially available anti-idiotypes. Recombinantly expressed antibodies derived from these pools showed high affinity for the adalimumab target, and no/low affinity for human IgG in general. The method also supports discovery of both blocking and non-blocking anti-idiotypes through integrated proteomics and functional selection approaches.
Speaker Bios
Chelsea Reitzel
Research Associate
Rapid Novor
Chelsea has spent the past five years developing wet lab techniques for polyclonal antibody sequencing at Rapid Novor. She holds a BSc in Biochemistry from the University of Waterloo and is currently pursuing an MSc in Molecular and Cellular Biology at the University of Guelph. Chelsea’s expertise lies at the intersection of protein science and immunology.
Teresa Nunez de Villavicencio Diaz, PhD
Senior Scientist, Polyclonal Antibody Sequencing
Rapid Novor
Teresa obtained her PhD in Biochemistry at the University of Western Ontario following the completion of a Master’s degree in Biotechnology. With 8+ years of experience, she approaches the challenges of polyclonal antibody sequencing through collaboration by leveraging her technical skills in Proteomics and Bioinformatics.